Insulet Corporation $PODD Shares Acquired by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. lifted its holdings in Insulet Corporation (NASDAQ:PODD) by 3.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 166,454 shares of the medical instruments supplier’s stock after buying an additional 5,450 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Insulet were worth $34,929,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Glenmede Investment Management LP lifted its holdings in Insulet by 1.6% in the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after acquiring an additional 35 shares during the period. Curi Capital LLC grew its stake in shares of Insulet by 0.8% during the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after purchasing an additional 36 shares during the period. Great Lakes Advisors LLC grew its stake in shares of Insulet by 1.5% during the 4th quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock worth $791,000 after purchasing an additional 40 shares during the period. Camarda Financial Advisors LLC lifted its stake in shares of Insulet by 0.5% in the second quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after purchasing an additional 40 shares during the period. Finally, Larson Financial Group LLC lifted its stake in shares of Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares during the period.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Sanford C. Bernstein lowered their target price on shares of Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Robert W. Baird reduced their price target on shares of Insulet from $360.00 to $248.00 in a research report on Thursday, May 7th. Canaccord Genuity Group decreased their price target on Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Wall Street Zen cut Insulet from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 27th. Finally, Bank of America dropped their price objective on Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Twenty-two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $235.25.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Negative Sentiment: Several firms, including Rosen, Robbins, Schall, Bronstein, and BFA Law, issued fresh notices about a securities class action against Insulet, highlighting alleged misrepresentations and safety issues tied to Omnipod devices and a defective cannula manufacturing claim. Article Title
• Negative Sentiment: The class-action filings may increase legal costs, management distraction, and uncertainty around potential damages, all of which can pressure investor sentiment toward Insulet. Article Title
• Neutral Sentiment: Royal Bank of Canada lowered its price target on Insulet from $280 to $245 but kept an outperform rating, signaling continued optimism even as analysts trimmed expectations. Article Title
• Neutral Sentiment: Commentary from market coverage suggested PODD also moved with broader medtech weakness, indicating some of the recent share-price pressure may be sector-related rather than company-specific. Article Title

Insiders Place Their Bets

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the acquisition, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. The trade was a 44.63% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.36% of the company’s stock.

Insulet Stock Up 0.5%

PODD stock opened at $162.06 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The company’s 50 day simple moving average is $152.73 and its 200-day simple moving average is $209.90. Insulet Corporation has a 12 month low of $138.79 and a 12 month high of $354.88. The firm has a market capitalization of $11.22 billion, a PE ratio of 37.69, a P/E/G ratio of 1.12 and a beta of 1.11.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. During the same period in the previous year, the firm posted $1.02 EPS. The company’s quarterly revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities analysts expect that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.